FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
TRENTON, N.J. (AP) — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit ...
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...
Eli Lilly and Co. has negotiated the right to market a knockoff version of the world's top-selling insulin, Lantus. The deal opens the door for Lilly and its German partner, Boehringer Ingelheim, to ...
INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...
Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on Thursday, intent on challenging the original drug’s dominance ...
Sanofi, rival drugmakers Lilly, Boehringer settle suit allowing rival to Lantus insulin in US This product image provided by Sanofi shows Lantus SoloStar, the French drugmaker's once-daily insulin in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results